Combining multikinase inhibitor foretinib with anti-PD-1 antibody treatment significantly inhibits tumor growth in a CRC mouse model, Foretinib (67.97 % inhibition) and PD-1 (76.69 % inhibition) individually inhibited tumor growth, but the inhibitory effect was significantly enhanced after the combination treatment (For + PD-1, 98.05 %). Here, PDCD1 is linked to colorectal carcinoma.